Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GNPAT | O15228 | 2/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.37 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.37 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | ALB | P02768 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3792833 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTKDM4ETHRBALOX15 | |
| SCHEMBL1129578 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTKDM4ETHRBALOX15 | |
| SCHEMBL29475246 | 0.87 | KDM4E (0.38) | SMN1; SMN2MAPTKDM4ETHRBALOX15 | |
| SCHEMBL7608409 | 0.87 | FOLH1 (0.38) | SMN1; SMN2MAPTKDM4ETHRBALOX15 | |
| SCHEMBL30804200 | 0.85 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPTKDM4ETHRBALOX15 | |
| SCHEMBL14611803 | 0.84 | SIRT6 (0.41) | SMN1; SMN2MAPTKDM4ETHRBALOX15 | |
| SCHEMBL12537172 | 0.82 | ALDH1A1 (0.38) | SMN1; SMN2MAPTKDM4ETHRBALOX15 | |
| SCHEMBL20160296 | 0.82 | KDM4E (0.35) | SMN1; SMN2MAPTKDM4ETHRBALOX15 | |
| SCHEMBL31167431 | 0.81 | ACE (0.32) | SMN1; SMN2MAPTKDM4ETHRBALOX15 | |
| SCHEMBL20077217 | 0.81 | MAPT (0.53) | SMN1; SMN2MAPTKDM4ETHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4417061-A1 | FOOD SUPPLEMENT FOR ANIMALS, PREPARATION METHOD THEREOF AND USE OF SAME | Adibio, S.l. (ES) | 2024-08-21 | — | — | EP | claimed |
| WO-2023062251-A1 | FOOD SUPPLEMENT FOR ANIMALS, PREPARATION METHOD THEREOF AND USE OF SAME | ADIBIO, S.L. (ES) | 2023-04-20 | — | — | WO | claimed |
| CN-122081135-A | Lactobacillus plantarum strain enriched in gamma-aminobutyric acid and application | — | 2026-05-26 | — | — | CN | disclosed |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | disclosed |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | UNIV CALIFORNIA (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260022384-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2026-01-22 | — | — | US | disclosed |
| US-20250375505-A1 | COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM | UNIV CALIFORNIA (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250295713-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES | DERMBIONT, INC. | 2025-09-25 | — | — | US | disclosed |
| EP-4417061-A1 | FOOD SUPPLEMENT FOR ANIMALS, PREPARATION METHOD THEREOF AND USE OF SAME | Adibio, S.l. (ES) | 2024-08-21 | — | — | EP | disclosed |
| US-12064459-B2 | Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes | DERMBIONT, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| CN-118435054-A | Compositions and methods for diagnosing and treating chronic kidney disease | 雀巢产品有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20210386802-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES | DERMBIONT, INC. | 2021-12-16 | — | — | US | disclosed |
| US-20210361725-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES | DERMBIONT, INC. | 2021-11-25 | — | — | US | disclosed |
| WO-2021202564-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING CELLULAR IDENTITY | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2021-10-07 | — | — | WO | disclosed |
| EP-3847257-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | Ospedale San Raffaele S.r.l. (IT) | 2021-07-14 | — | — | EP | disclosed |
| US-11040077-B2 | Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes | DERMBIONT, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| WO-2021076999-A1 | FECAL-DERIVED STERILE POSTBIOTIC COMPOSITION AND METHOD THEREFOR | HUBBLE BIOSCIENCE INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20210038654-A1 | COMPOSITIONS FOR MODULATING GUT MICROFLORA POPULATIONS, ENHANCING DRUG POTENCY AND TREATING CANCER, AND METHODS FOR MAKING AND USING SAME | PERSEPHONE BIOSCIENCES INC. | 2021-02-11 | — | — | US | disclosed |
| US-20200345799-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES | DERMBIONT, INC. | 2020-11-05 | — | — | US | disclosed |
| CN-102112124-A | Protection of normal cells | UNIV FLORIDA ATLANTIC | 2011-06-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375505-A1 | COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM | CYP27A1, LIPC, CYP46A1 | SMN1; SMN2 4332/4885MAPT 1772/4885KDM4E 3711/4885 |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | IDO1, INMT, IDO2 | SMN1; SMN2 1923/4885MAPT 1253/4885KDM4E 553/4885 |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | SMN1; SMN2 2156/4885MAPT 3150/4885KDM4E 124/4885 |
| US-20260022384-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | ASNS, AARS1, NARS1 | SMN1; SMN2 3592/4885MAPT 2780/4885KDM4E 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.